Status:
COMPLETED
Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Conditions:
Unresectable Hepatocellular Carcinoma
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more than 28%. After diagnosis, the average survival rate of patient is less than 50% in 6 month, less than 24% in...
Detailed Description
Liver cancer is a highly invasive malignancy and the rate of surgical resection is no more than 28%. The TACE treatment, under the theoretical basis of blood supply of Liver cancer, is obviously bette...
Eligibility Criteria
Inclusion
- the participation is entirely voluntary, good at compliance, sign the informed consent form in person;
- diagnosed to be hepatocellular carcinoma by clinical method, imaging method and tumor markers; and the surgeons determine who can not undergo surgery;
- confirmed to recurrent after surgery by pathology;
- KPS score of physical state ≥ 60 points;
- liver function is Child-Pugh A or B class
Exclusion
- General situation is poor and liver function Child-Pugh is C class;
- there is a serious heart, kidney and blood system diseases in patients;
- poor compliance;
- there is allergy history of biological agents or in a state of allergy;
- pregnancy and breast-feeding women
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00829465
Start Date
December 1 2008
End Date
December 1 2010
Last Update
April 1 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.